Phase 3 Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

The requested reference [50ebaf8e9788e3c1bb408b3746aafa6d450d3be8] no longer exists in our database. It has been replaced by the current reference: [919340859a39618f840c7d000f4dd805c1ec0df0]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a randomized, double‐blind, placebo‐parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.
Epistemonikos ID: 0c7547357a9ef409f1e29e2696cc5e2c0f7b8af0
First added on: May 15, 2024